Evidence map›Paper›PMID 26937447›Full record

ArticleCurrent opinion in behavioral sciences2015

Using Intermediate Cognitive Endpoints to Facilitate Translational Research in Psychosis.

Gary Gilmour, Francois Gastambide, Hugh M Marston, Mark E Walton

Open access · hybridAbstract read
In one paragraph

Article in Current opinion in behavioral sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gary GilmourIn Vivo Pharmacology, Eli Lilly & Co. Ltd., Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.
Francois GastambideIn Vivo Pharmacology, Eli Lilly & Co. Ltd., Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.
Hugh M MarstonIn Vivo Pharmacology, Eli Lilly & Co. Ltd., Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.
Mark E WaltonDepartment of Experimental Psychology, University of Oxford, 9 South Parks Road, Oxford, OX1 3UD, U.K.
Eli Lilly (United Kingdom) · GBUniversity of Oxford · GB

Funding

Wellcome Trust 090051
6 · The paper itself

Abstract

Recent advances in the understanding of psychosis have uncovered potential for a paradigm shift in related drug discovery efforts. The study of psychosis is evolving from its origins in serendipity and empiricism to more formal, hypothesis driven accounts of the cognitive substrates underlying hallucinations and delusions. Recent evidence suggests that misattribution of salience and abnormal prediction error might underlie some forms of psychosis. If substantiated, such intermediate constructs could significantly facilitate translational research for drug discovery. Aberrant salience and prediction error can be assayed with simple tests of associative learning in both species, and a convincing back translation of effects, when combined with measures of neurotransmitter release and brain activity could for the first time allow robust, causal connections to be made between molecular mechanisms in rodents and symptoms in patients.

Identifiers

PMID26937447
PMCPMC4770458
OpenAlexW255284956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.